Trials / Terminated
TerminatedNCT03448692
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
A PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06730512 | Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion. |
Timeline
- Start date
- 2018-10-15
- Primary completion
- 2023-02-14
- Completion
- 2023-02-14
- First posted
- 2018-02-28
- Last updated
- 2024-04-18
- Results posted
- 2024-04-18
Locations
110 sites across 12 countries: United States, Canada, Czechia, France, Germany, Italy, Japan, Mexico, Poland, Slovakia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03448692. Inclusion in this directory is not an endorsement.